The KRAS Mutation: Why It Matters in NSCLC

The KRAS gene, short for Kirsten rat sarcoma viral oncogene homolog, is one of the most frequently mutated genes in cancer. In NSCLC, the G12C mutation—a single amino acid substitution at position 12—occurs in approximately 13% of cases, making it a critical target for therapy. This mutation locks the KRAS protein in an “always-on” state, driving uncontrolled cell growth and tumor progression.

Historically, KRAS mutations were associated with poor prognosis and limited treatment options. Chemotherapy and immunotherapy were the standard approaches, but response rates varied widely. The advent of KRAS G12C inhibitors has transformed the landscape, offering a precision medicine approach for a subset of patients who previously had few alternatives.

KRAS G12C Inhibitors: How They Operate

KRAS G12C inhibitors, such as sotorasib (Lumakras) and adagrasib (Krazati), work by irreversibly binding to the mutant KRAS protein, locking it in its inactive state. This halts the signaling cascade that promotes cancer cell survival and proliferation. Unlike chemotherapy, which attacks all rapidly dividing cells, these drugs specifically target the mutated protein, reducing systemic toxicity.

Approved Therapies

Both drugs are administered orally, offering a convenient alternative to intravenous therapies. However, they are not without challenges. Resistance can develop over time, and side effects—such as diarrhea, liver enzyme elevations, and fatigue—require careful management.

The Oncology Nurse’s Role: From Education to Side Effect Management

Oncology nurses are often the first point of contact for patients navigating KRAS-targeted therapies. Their responsibilities span education, monitoring, and emotional support, ensuring patients understand their treatment and adhere to protocols. Here’s how nurses make a difference:

1. Patient Education

Many patients are unfamiliar with the concept of targeted therapy or the specifics of KRAS mutations. Nurses play a critical role in:

• Explaining the science: Simplifying complex concepts, such as how KRAS inhibitors differ from chemotherapy or immunotherapy.
• Setting expectations: Clarifying that these drugs are not a cure but can extend progression-free survival and improve quality of life.
• Discussing testing: Emphasizing the importance of comprehensive genomic testing to confirm KRAS G12C status before treatment.

“It’s been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for over four decades, researchers couldn’t figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor,”

2. Monitoring and Managing Side Effects

While KRAS inhibitors are generally better tolerated than chemotherapy, they can cause side effects that impact quality of life. Nurses monitor patients for:

• Gastrointestinal issues: Diarrhea, nausea, and vomiting are common and may require antiemetics or dose adjustments.
• Hepatotoxicity: Elevated liver enzymes (e.g., ALT, AST) necessitate regular blood work and potential dose interruptions.
• Fatigue: A pervasive side effect that can be managed through lifestyle modifications and supportive care.
• Respiratory symptoms: Shortness of breath or cough may indicate pneumonitis, a rare but serious complication.

Nurses collaborate with pharmacists and physicians to develop individualized management plans, ensuring patients remain on therapy as long as it is beneficial.

3. Navigating Resistance and Emerging Therapies

Despite their efficacy, KRAS inhibitors are not a permanent solution. Resistance mechanisms, such as secondary mutations or activation of alternative signaling pathways, can limit their long-term effectiveness. Nurses help patients understand:

• When to expect resistance: Most patients develop resistance within 6–12 months of starting therapy.
• Next steps: Options may include clinical trials, combination therapies, or switching to alternative treatments like immunotherapy or chemotherapy.
• Emerging therapies: New KRAS inhibitors, such as divarasib and GDC-6036, are in development, with some showing promise in early-phase trials.

For example, early data from Moffitt Cancer Center suggest that next-generation KRAS inhibitors may overcome resistance seen with first-generation drugs like sotorasib and adagrasib.

Combination Therapies: The Next Frontier

To improve outcomes, researchers are exploring combination therapies that pair KRAS inhibitors with other agents. One promising approach is combining adagrasib with cetuximab, an EGFR inhibitor. Early clinical trials have shown that this combination can:

• Enhance tumor cell death by targeting multiple pathways.
• Delay the onset of resistance.
• Improve response rates in patients who have progressed on single-agent KRAS inhibitors.

In December 2025, the FDA granted accelerated approval to adagrasib plus cetuximab for patients with KRAS G12C-mutated NSCLC who have received prior systemic therapy. This approval underscores the potential of combination strategies to extend the benefits of KRAS-targeted therapy.

What Nurses Need to Grasp About Combination Therapy

• Increased toxicity: Combining adagrasib with cetuximab may heighten side effects, such as skin rash and diarrhea.
• Patient selection: Not all patients are candidates for combination therapy; factors like performance status and prior treatments must be considered.
• Monitoring: Close surveillance for adverse events is essential, with dose adjustments as needed.

Challenges and Opportunities in KRAS-Targeted Care

While KRAS inhibitors represent a major advance, several challenges remain:

1. Access and Equity

• Cost: KRAS inhibitors are expensive, with annual costs exceeding $200,000. Nurses advocate for patients by connecting them with financial assistance programs and insurance navigators.
• Testing disparities: Not all patients have access to comprehensive genomic testing, which is essential for identifying KRAS mutations. Nurses can educate patients and providers about the importance of testing and available resources.

2. Patient Adherence

Oral therapies require strict adherence to dosing schedules. Nurses address barriers to adherence by:

• Providing clear instructions on how and when to take medications.
• Using pill organizers or reminder apps to help patients stay on track.
• Addressing side effects proactively to prevent treatment interruptions.

3. Emotional and Psychological Support

A diagnosis of advanced NSCLC can be overwhelming. Nurses provide emotional support by:

• Connecting patients with support groups and mental health resources.
• Encouraging open communication about fears and concerns.
• Helping patients set realistic goals and maintain hope.

FAQs: What Patients and Caregivers Need to Know

Q: How do I know if I have the KRAS G12C mutation?

A: The only way to confirm a KRAS G12C mutation is through comprehensive genomic testing, which analyzes your tumor’s DNA. This can be done using a tissue biopsy or a liquid biopsy (blood test). Ask your oncologist about testing options if you have been diagnosed with NSCLC.

Q: Are KRAS inhibitors a cure for lung cancer?

A: No. KRAS inhibitors are not a cure, but they can shrink tumors, sluggish disease progression, and improve quality of life. Most patients will eventually develop resistance, at which point other treatments may be considered.

Q: What are the most common side effects of KRAS inhibitors?

The most frequently reported side effects include:

• Diarrhea
• Nausea and vomiting
• Fatigue
• Elevated liver enzymes
• Muscle or joint pain

Most side effects are manageable with supportive care and dose adjustments.

Q: Can I take KRAS inhibitors if I’ve already had chemotherapy or immunotherapy?

A: Yes. KRAS inhibitors are approved for patients who have previously received systemic therapy, such as chemotherapy or immunotherapy. Your oncologist will determine if you are a candidate based on your treatment history and overall health.

Q: What happens if my cancer stops responding to KRAS inhibitors?

A: If your cancer progresses on a KRAS inhibitor, your oncologist may recommend:

• Switching to a different KRAS inhibitor (if available).
• Enrolling in a clinical trial for emerging therapies.
• Considering combination therapies, such as adagrasib plus cetuximab.
• Transitioning to other treatments, such as immunotherapy or chemotherapy.

The Future of KRAS-Targeted Therapy

The approval of KRAS G12C inhibitors marked a turning point in the treatment of NSCLC, but the field is rapidly evolving. Researchers are exploring:

• Next-generation KRAS inhibitors: Drugs like divarasib and GDC-6036 aim to overcome resistance and improve efficacy.
• Pan-KRAS inhibitors: Therapies that target multiple KRAS mutations, not just G12C, are in early development.
• Combination strategies: Pairing KRAS inhibitors with immunotherapy, chemotherapy, or other targeted agents to enhance response rates.
• Early-stage treatment: Clinical trials are investigating KRAS inhibitors in earlier stages of NSCLC, including as adjuvant or neoadjuvant therapy.

For oncology nurses, staying informed about these advances is critical. Continuing education, such as podcasts and webinars, can help nurses provide the most up-to-date guidance to their patients.